Want to see RXST full AI Analyst Report?
RXST Stock Chart & Stats
$5.19
$0.28(5.49%)
At close: 4:00 PM EDT
$5.19
$0.28(5.49%)
Day’s Range― - ―
52-Week Range$4.48 - $13.22
Previous CloseN/A
Volume112.75K
Average Volume (3M)1.34M
Market Cap
$248.79M
Enterprise Value$47.39
Total Cash (Recent Filing)$217.88M
Total Debt (Recent Filing)$10.83M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Aug 05, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding41,396,610
10 Day Avg. Volume1,325,215
30 Day Avg. Volume1,336,033
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)1.56
Price to Sales (P/S)3.19
P/FCF Ratio-22.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.07Price Target Upside55.52% Upside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)-1.24
Revenue Forecast (FY)$136.12M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsProduct-level economics show persistently high gross margins, driven by LAL consumable mix and limited variable cost pressure. Sustained 70%+ margins provide durable operating leverage as volumes scale, enabling reinvestment in commercialization while cushioning margin volatility.
Conservative Balance SheetVery low leverage and ample equity give the company financial flexibility to fund operations, R&D, and international rollouts without near-term refinancing stress. This conservative structure supports sustained investment through the commercialization curve.
Strategic Alcon CollaborationA non‑exclusive development and commercialization partnership with Alcon materially de-risks commercialization: upfront cash improves runway, milestone and royalty economics create long-term revenue optionality, and Alcon's global commercial reach accelerates adoption of adjustable-lens technology.
Bears Say
Negative Cash Flow And Ongoing LossesPersistent negative operating and free cash flow means the business is not yet self-funding; continued losses will require either draw on cash reserves, financing, or partnership monetization. This constrains strategic optionality and raises execution risk if growth stalls.
Revenue Slowdown / Negative Growth TrendAfter prior rapid growth, sequential revenue weakness reflects adoption and utilization headwinds. A sustained revenue contraction limits ability to achieve scale economics, delays margin expansion, and increases reliance on expense control or external funding for long-term plans.
Weak Capital Placements (LDD Sales)LDD installations are the primary driver of repeat LAL consumable sales; subdued capital placements slow installed base growth and constrain recurring revenue expansion. Slower clinic adoption prolongs the payback period on commercial investments and limits scale benefits.
RxSight News
RXST FAQ
What was RxSight’s price range in the past 12 months?
RxSight lowest stock price was $4.48 and its highest was $13.22 in the past 12 months.
What is RxSight’s market cap?
RxSight’s market cap is $248.79M.
When is RxSight’s upcoming earnings report date?
RxSight’s upcoming earnings report date is Aug 05, 2026 which is in 3 days.
How were RxSight’s earnings last quarter?
RxSight released its earnings results on May 06, 2026. The company reported -$0.38 earnings per share for the quarter, missing the consensus estimate of -$0.299 by -$0.081.
Is RxSight overvalued?
According to Wall Street analysts RxSight’s price is currently Undervalued.
Does RxSight pay dividends?
RxSight does not currently pay dividends.
What is RxSight’s EPS estimate?
RxSight’s EPS estimate is -0.33.
How many shares outstanding does RxSight have?
RxSight has 41,396,610 shares outstanding.
What happened to RxSight’s price movement after its last earnings report?
RxSight reported an EPS of -$0.38 in its last earnings report, missing expectations of -$0.299. Following the earnings report the stock price went down -14.454%.
Which hedge fund is a major shareholder of RxSight?
Currently, no hedge funds are holding shares in RXST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RxSight Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$8.07 (55.52% Upside)
$8.07 (55.52% Upside)
Blogger Sentiment
Bullish
RXST Sentiment 100%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 148.6K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.89%
Trailing 12-Months
Company Description
RxSight
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
RXST Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: operational positives include stabilized LAL procedure volumes, improved gross margin in Q1, a major commercial milestone (300,000 implants), early signs of success from customer reengagement programs, and maintained full-year revenue guidance. Offsetting these are sizable near-term challenges — an 18% YoY revenue decline, weak LDD capital placements (only 20 sold), a Q1 net loss of $15.9M, increased SG&A/OpEx investments, and anticipated margin pressure from higher-cost inventory that will weigh on near-term profitability. Management projects gradual sequential improvement and is investing to drive longer-term growth, but near-term financial headwinds and modest 2026 volume expectations temper the outlook.View all RXST earnings summariesRXST Stock 12 Month Forecast
Average Price Target
$8.07
▲(55.52% Upside)
Technical Analysis
Delcath Systems
―
Senseonics Holdings
―
Butterfly Network
―
NeuroPace
―
Ceribell, Inc.
―
Ownership Overview
6.36% Insiders
15.45% Mutual Funds
1.22% Other Institutional Investors
63.25% Public Companies and
Individual Investors